PP_1170x120_10-25-21

Catalent

Catalent agrees to buy Juniper Pharmaceuticals

Catalent agrees to buy Juniper Pharmaceuticals

SOMERSET, N.J. – Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products,  announced that it has agreed to acquire Juniper Pharmaceuticals, including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug development and manufacturing capabilities in the U.S. and Europe,